Skip to main content
. 2019;21(1):15–20.

Table 4.

Immunotherapy Agents for Testicular Cancer

Testicular Current Role Mechanism Outcomes
Brentuximab vedotin Highly pre-treated patients with germ-cell tumors Antibody-drug conjugate Early signs of clinical activity and immunomodulatory effects
Immune checkpoint inhibitors Seminoma and non-seminomatous germ-cell tumors Checkpoint inhibitors An option, 73% expression PD-L1